We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Repercussions from the failed Plavix settlement continue at Bristol-Myers Squibb (BMS), with the apparently forced departure of CEO Peter Dolan and Senior Vice President and General Counsel Richard Willard on the recommendation of a federal monitor.
Adolor’s stock took a major hit after the company and GlaxoSmithKline announced data showing that their new drug alvimopan, designed to treat opioid-induced bowel dysfunction (OBD), was ineffective in two of three clinical trials.
Cardinal Health Aug. 28 announced it had suspended production, sales, repairs and installations of its Alaris SE infusion pump after the government seized approximately 1,300 of the devices Aug. 25.